<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04585022</url>
  </required_header>
  <id_info>
    <org_study_id>KF 01-309171</org_study_id>
    <nct_id>NCT04585022</nct_id>
  </id_info>
  <brief_title>Whole Blood Metal Ion Concentrations in Metal-on-metal Total Hip Arthroplasty and Hip Resurfacing</brief_title>
  <official_title>Whole Blood Metal Ion Concentrations in Metal-on-metal Total Hip Arthroplasty and Hip Resurfacing - A Randomized Controlled Trial With 5-years Follow up Including 75 Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hvidovre University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hvidovre University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators aimed to investigate the possible differences in metal ion concentrations&#xD;
      in patients following one of two types of metal-on-metal articulating hip prosthesis&#xD;
      regarding chromium and cobalt concentration, radiological findings, patient reported outcome&#xD;
      measures and rate of revision at 5-years follow up.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The metal-on-metal large-diameter-head (MoM-LDH) hip replacements increased in popularity&#xD;
      during the start of the 21st century. Subsequently reports raised concerns regarding adverse&#xD;
      reactions due to elevated chromium (Cr) and cobalt (Co) concentrations as well as high rates&#xD;
      of other complications and revisions.&#xD;
&#xD;
      This was a single center parallel-group randomized controlled trial. The primary outcome was&#xD;
      to compare Cr and Co concentrations at 5-years follow up following MoM-LDH total hip&#xD;
      arthroplasty (MoM-LDH-THA) or MoM-LDH hip resurfacing (MoM-LDH-HR).&#xD;
&#xD;
      Secondary outcomes were radiological findings, patient reported outcome measures and revision&#xD;
      rate at 5-years follow up.&#xD;
&#xD;
      The study was prematurely terminated in 2012 due to alerts and safety communications from the&#xD;
      Danish national regulatory agency regarding early failure rates and high incidence of ARMD in&#xD;
      patients with MoM hip implants [13]. At that time the study population consisted of 75&#xD;
      patients out of 200 planned for inclusion.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    High early failure rates and adverse reactions in similar devices&#xD;
  </why_stopped>
  <start_date type="Actual">November 1, 2006</start_date>
  <completion_date type="Actual">January 11, 2017</completion_date>
  <primary_completion_date type="Actual">January 11, 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Outcomes Assessor)</masking>
    <masking_description>Both the care provider and patient were blinded until day of surgery. The laboratory analyzing blood metal concentrations were blinded to treatment allocation throughout the study.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Metal ion concentrations in blood</measure>
    <time_frame>at 5 years follow up</time_frame>
    <description>Chromium and cobalt concentrations in whole blood</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Patient reported outcome measure 1</measure>
    <time_frame>at 5 years follow up</time_frame>
    <description>Harris Hip Score (0-100, higher values meaning better outcome)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient reported outcome measure 2</measure>
    <time_frame>at 5 years follow up</time_frame>
    <description>SF-36 (0-100, higher values meaning better outcome)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Implant survival</measure>
    <time_frame>at 5 years follow up</time_frame>
    <description>Rate of revision</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">75</enrollment>
  <condition>Osteoarthritis, Hip</condition>
  <arm_group>
    <arm_group_label>Magnum</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>A metal-on-metal large diameter head total hip arthroplasty</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Recap</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>A metal-on-metal hip resurfacing arthroplasty</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Magnum, Zimmer Biomet, Warsaw, IN</intervention_name>
    <arm_group_label>Magnum</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Recap, Zimmer Biomet, Warsaw, IN</intervention_name>
    <arm_group_label>Recap</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Primary or secondary hip osteoarthritis eligible for hip replacement surgery&#xD;
&#xD;
          -  Able to give informed consent&#xD;
&#xD;
          -  Able to complete follow up consultations&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Earlier or present infection of the hip&#xD;
&#xD;
          -  Severe systemic or metabolic disease leading to weakening of the bone&#xD;
&#xD;
          -  Severe congenital hip dysplasia&#xD;
&#xD;
          -  Osteoporosis and/or renal disease&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Anders Troelsen, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hvidovre University Hospital</affiliation>
  </overall_official>
  <verification_date>October 2020</verification_date>
  <study_first_submitted>September 23, 2020</study_first_submitted>
  <study_first_submitted_qc>October 10, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">October 14, 2020</study_first_posted>
  <last_update_submitted>October 28, 2020</last_update_submitted>
  <last_update_submitted_qc>October 28, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">October 29, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Hvidovre University Hospital</investigator_affiliation>
    <investigator_full_name>Anders Troelsen</investigator_full_name>
    <investigator_title>MD, PhD, dr.med., Professor</investigator_title>
  </responsible_party>
  <keyword>Metal ion concentration</keyword>
  <keyword>Total hip arthroplasty</keyword>
  <keyword>Hip resurfacing</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoarthritis, Hip</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cimetidine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>No IPD are to be shared with other researchers.</ipd_description>
  </patient_data>
  <pending_results>
    <submitted>September 30, 2021</submitted>
    <returned>October 28, 2021</returned>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

